Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Peripheral T Cell Lymphoma
- Transformed Mycosis Fungoides
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: Non-RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04101331
- Collaborators
- Not Provided
- Investigators
- Study Director: Cassandra Choe-Juliak, MD Affimed Inc. Principal Investigator: Won Seog Kim, Dr Samsung Medical Center Principal Investigator: Steven Horwitz, MD Memorial Sloan Kettering Cancer Center